<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647227</url>
  </required_header>
  <id_info>
    <org_study_id>ATHN 16</org_study_id>
    <nct_id>NCT04647227</nct_id>
  </id_info>
  <brief_title>SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors</brief_title>
  <official_title>Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients With Hemophilia A or B With Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Thrombosis and Hemostasis Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LFB USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>American Thrombosis and Hemostasis Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IV multi-center, US-centric, open-label, safety study enrolling participants with&#xD;
      Hemophilia A or B with inhibitors aged 12 to 65 years, inclusive, who are either on long term&#xD;
      prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding&#xD;
      event (BE), or who are not on prophylactic treatment who may need to control a BE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To evaluate the safety of SEVENFACT® when used to treat bleeding episodes in participants&#xD;
      with Hemophilia A or B with inhibitors either with or without prophylactic treatment&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Phase IV multi-center, US-centric, open-label, safety study enrolling participants with&#xD;
      Hemophilia A and B with inhibitors aged 12 to 65 years, inclusive, who are either on long&#xD;
      term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough&#xD;
      bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      Participants will be followed longitudinally from the time of enrollment to the end of their&#xD;
      participation in the study. The maximal study duration for any participant in the study will&#xD;
      be up to 2 years from the time of enrollment.&#xD;
&#xD;
      Target Accrual:&#xD;
&#xD;
      This is a multi-site study in which it is anticipated approximately 28 to 55 participants&#xD;
      will be enrolled in order to achieve treatment of approximately 100 bleeding events. The&#xD;
      study will target enrollment of a minimum of 23 participants on emicizumab prophylactic&#xD;
      treatment and 5 participants on other treatments.&#xD;
&#xD;
      Data Analysis:&#xD;
&#xD;
      Sample Size Determination:&#xD;
&#xD;
      Results from the Haven 1 study were used to calculate the annual bleeding rates (ABR) in&#xD;
      individuals receiving prophylactic treatment. These were calculated at an ABR of three for&#xD;
      participants receiving emicizumab prophylactic treatment and 20 for participants receiving&#xD;
      other treatments.&#xD;
&#xD;
      Based on these data, it was calculated that between 28 and 55 participants would be necessary&#xD;
      to reach 100 BEs with a minimum of 23 participants on emicizumab prophylactic treatment and 5&#xD;
      participants on other treatments.&#xD;
&#xD;
      Analysis Populations:&#xD;
&#xD;
      The Safety Analysis Set is defined as all participants who received at least a single dose of&#xD;
      SEVENFACT®. All analyses of safety will be performed based on the safety population, and&#xD;
      participants will be analyzed according to the dose of SEVENFACT® that they actually&#xD;
      received.&#xD;
&#xD;
      Baseline Characteristics:&#xD;
&#xD;
      Baseline characteristics will be summarized using descriptive statistics for continuous&#xD;
      variables, and frequencies and percentages for categorical variables.&#xD;
&#xD;
      Safety Evaluations:&#xD;
&#xD;
      All Adverse Events (AEs) will be graded for severity utilizing Common Terminology Criteria&#xD;
      for Adverse Events (CTCAE) v5.0 and coded using Medical Dictionary of Regulatory Activities&#xD;
      (MedDRA) version 23.x. The number and percentage of participants with treatment-emergent AEs&#xD;
      (TEAEs), serious AEs (SAEs), serious TEAEs and treatment related TEAEs (i.e., adverse drug&#xD;
      reactions [ADRs]) will be presented for all participants.&#xD;
&#xD;
      The number of TEAEs, as well as the number and percentage of participants with TEAEs, serious&#xD;
      TEAEs, and treatment-related TEAEs will be presented by MedDRA System Organ Class (SOC) and&#xD;
      preferred term for all participants.&#xD;
&#xD;
      The number and percentage of participants with treatment-emergent adverse event and/or&#xD;
      allergic and anaphylactic reactions will be presented for all participants.&#xD;
&#xD;
      Efficacy Evaluations:&#xD;
&#xD;
      There are no pre-specified efficacy endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>ATHN 16 is a phase IV multi-center, US-centric, open-label, safety study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants and percentage of Safety Events (AEs)</measure>
    <time_frame>From time of consent through BE onset until 3 days after last dose of SEVENFACT®.</time_frame>
    <description>Adverse Events and SAEs defined by the European Haemophilia Safety Surveillance System 2018 (EUHASS) and Serious Adverse Events (SAEs) as defined by the US Food and Drug Association.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Hemophilia A With Inhibitor</condition>
  <condition>Hemophilia B With Inhibitor</condition>
  <arm_group>
    <arm_group_label>Hemophilia A and B Cases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SEVENFACT® has been approved for the treatment of bleeding events in individuals with hemophilia A or B with inhibitors. This study is intended to further investigate the safety and tolerability of SEVENFACT in participants with hemophilia A or B with inhibitors in the presence or absence of prophylactic therapies. Dosing will be at the discretion of the attending physician, and each participant will be supplied with the equivalent of nine 75 µg/kg doses, which aligns with the recommended dosing schedule as provided in SEVENFACT's United States Prescribing Information (USPI). In the event of a bleeding episode (BE), the participant will either self-administer the correct dose under the guidance of the treating investigator or the dose will be administered at a treatment facility.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>coagulation factor VIIa [recombinant]-jncw</intervention_name>
    <description>a transgenically produced, activated, recombinant, human factor VII (rhFVIIa) protein with the brand name of SEVENFACT®. This protein is a clotting factor in the coagulation cascade that is produced in and purified from the milk of transgenic rabbits. SEVENFACT is approved for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors.</description>
    <arm_group_label>Hemophilia A and B Cases</arm_group_label>
    <other_name>SEVENFACT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have a diagnosis of hemophilia A or B with inhibitors.&#xD;
&#xD;
          2. Be 12 - 65 years of age inclusive&#xD;
&#xD;
          3. Be capable of understanding and willing to comply with the conditions of the protocol&#xD;
             or have a legal guardian who is capable of understanding and complying with the&#xD;
             conditions of the protocol&#xD;
&#xD;
          4. Have read, understood, and documented written informed consent/assent&#xD;
&#xD;
          5. Be able to provide medical evidence through prior medical history of previous&#xD;
             inhibitor levels&#xD;
&#xD;
          6. Be willing and able to use the ATHN mobile application or a paper diary to document&#xD;
             BEs and medication usage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a disorder of hemostasis in addition to Hemophilia A or B&#xD;
&#xD;
          2. Have a known or suspected intolerance or hypersensitivity to SEVENFACT® or its&#xD;
             ingredients&#xD;
&#xD;
          3. Have a known allergy or hypersensitivity to rabbits or rabbit proteins&#xD;
&#xD;
          4. Are receiving prophylactic treatment for bleeding with a drug or biologic that is not&#xD;
             approved for this use by the FDA&#xD;
&#xD;
          5. Have had implantation of an investigational medical device within the prior 6 months&#xD;
&#xD;
          6. Have received an investigational drug within 30 days of the baseline visit&#xD;
&#xD;
          7. Have an elective surgical procedure planned during the duration of their participation&#xD;
             in the study*&#xD;
&#xD;
          8. Have any life-threatening disease, or other disease or condition which, in the&#xD;
             investigator's judgment, could pose a potential hazard to the patient or interfere&#xD;
             with study participation or study outcome (e.g., a history of non responsiveness to&#xD;
             bypassing products or thromboembolic disease)&#xD;
&#xD;
               -  Should a participant require an unplanned surgery, the participant will not be&#xD;
                  withdrawn from the study unless the investigator deems it necessary. Instead, the&#xD;
                  participant will receive standard of care treatment as determined by the&#xD;
                  attending physician. If the participant is not withdrawn from the study, the&#xD;
                  participant's participation in the study will be paused until the investigator&#xD;
                  feels it is safe for them to continue.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tammuella Chrisentery-Singleton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louisiana Center for Advanced Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol Fedor, ND, RN, CCRC</last_name>
    <phone>(800)-360-2846</phone>
    <phone_ext>122</phone_ext>
    <email>cfedor@athn.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikki Hirsh, MS</last_name>
    <phone>800-360-2846</phone>
    <email>nhirsh@athn.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Hemophilia and Thrombosis Center at Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Knoll, MD</last_name>
      <email>cknoll@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Christine Knoll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Institute for Children</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Doris Quon, MD</last_name>
      <email>dquon@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Doris Quon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Inherited Blood Disorders</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Crook</last_name>
      <email>NCrook@c3dibd.org</email>
    </contact>
    <investigator>
      <last_name>Amit Soni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Davis UC Davis Hemostasis and Thrombosis Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Giermasz, MD</last_name>
      <email>Giermasz@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Giermasz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Hemophilia Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Guerrera, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Guerrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory, Adult Division</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Glaivy Batsuli, MD</last_name>
      <email>gbatsul@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Glaivy Batsuli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willett Children's Hospital at Memorial University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evangeline Brown, MD</last_name>
      <email>evangeline.brown@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Evangeline Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana Center for Bleeding and Clotting Disorders, Tulane</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amina Rafique, MD</last_name>
      <email>arafique@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Amina Rafique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana Center for Advanced Medicine</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamuella Chrisentery-Singleton, MD</last_name>
      <email>tsingleton@msadvancedmedicine.com</email>
    </contact>
    <contact_backup>
      <last_name>Jesus Monico</last_name>
      <email>jmonico@msadvancedmedicine.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tammuella Chrisentery-Singleton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meera Chitlur, MD</last_name>
      <email>mchitlur@dmc.org</email>
    </contact>
    <investigator>
      <last_name>Meera Chitlur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philip Kuriakose, MD</last_name>
      <email>pkuriak1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Philip Kuriakose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MSU Center for Bleeding and Clotting Disorders</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Burghardt</last_name>
      <email>annarn@msu.edu</email>
    </contact>
    <investigator>
      <last_name>Roshni Kulkarni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Bleeding and Clotting Disorders, M Health</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Reding, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mark Reding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Comprehensive Hemophilia Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rajiv Pruthi, MD</last_name>
      <email>pruthi.rajiv@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Rajiv Pruthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mississippi Center for Advanced Medicine</name>
      <address>
        <city>Madison</city>
        <state>Mississippi</state>
        <zip>39110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wendy Thomson</last_name>
      <email>wthomson@msadvancedmedicine.com</email>
    </contact>
    <investigator>
      <last_name>Spencer Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Regional Hemophilia Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Amos, MD</last_name>
      <email>lamos@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Lauren Amos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health, Long Island Jewish</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suchitra Acharya, MD</last_name>
      <email>Sacharya@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Suchitra Acharya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Center for Bleeding and Clotting Disorders</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Osman Khan, MD</last_name>
      <email>osman-khan@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Osman Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gulf States Hemophilia and Thrombophilia Center-University of Texas Health Science Center @Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Escobar, MD</last_name>
      <email>Miguel.Escobar@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Miguel Escobar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia A</keyword>
  <keyword>Hemophilia B</keyword>
  <keyword>bleeding event</keyword>
  <keyword>prophylactic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

